메뉴 건너뛰기




Volumn 98, Issue 5, 2017, Pages 425-434

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia

Author keywords

inotuzumab ozogamicin; relapsed acute lymphoblastic leukemia

Indexed keywords

CALICHEAMICIN; CD22 ANTIGEN; INOTUZUMAB OZOGAMICIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85014795073     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12862     Document Type: Review
Times cited : (41)

References (41)
  • 2
    • 79958043675 scopus 로고    scopus 로고
    • (eds)., National Cancer Institute., Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Last accessed 1 December 2016
    • Howlader N, Noone AM, Krapcho M, et al. (eds). SEER cancer statistics review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Last accessed 1 December 2016
    • SEER cancer statistics review, 1975-2013
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 3
    • 79952078495 scopus 로고    scopus 로고
    • Biology, risk stratification, and therapy of pediatric acute leukemias: an update
    • Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29:551–565.
    • (2011) J Clin Oncol , vol.29 , pp. 551-565
    • Pui, C.H.1    Carroll, W.L.2    Meshinchi, S.3    Arceci, R.J.4
  • 4
    • 0032482394 scopus 로고    scopus 로고
    • Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
    • Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671.
    • (1998) N Engl J Med , vol.338 , pp. 1663-1671
    • Nachman, J.B.1    Sather, H.N.2    Sensel, M.G.3
  • 5
    • 84863772728 scopus 로고    scopus 로고
    • Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group
    • Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30:1663–1669.
    • (2012) J Clin Oncol , vol.30 , pp. 1663-1669
    • Hunger, S.P.1    Lu, X.2    Devidas, M.3
  • 6
    • 76749111534 scopus 로고    scopus 로고
    • Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001
    • Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010;24:406–418.
    • (2010) Leukemia , vol.24 , pp. 406-418
    • Mitchell, C.1    Richards, S.2    Harrison, C.J.3    Eden, T.4
  • 7
    • 84865168175 scopus 로고    scopus 로고
    • Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
    • Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165–1174.
    • (2012) Blood , vol.120 , pp. 1165-1174
    • Pui, C.H.1    Mullighan, C.G.2    Evans, W.E.3    Relling, M.V.4
  • 8
    • 60949101218 scopus 로고    scopus 로고
    • Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
    • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
    • (2009) J Clin Oncol , vol.27 , pp. 911-918
    • Huguet, F.1    Leguay, T.2    Raffoux, E.3
  • 9
    • 84903557769 scopus 로고    scopus 로고
    • Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance)
    • abstract
    • Advani AS, Sanford B, Luger S, et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance). Blood. 2013;122:3903; abstract.
    • (2013) Blood , vol.122 , pp. 3903
    • Advani, A.S.1    Sanford, B.2    Luger, S.3
  • 10
    • 28444490353 scopus 로고    scopus 로고
    • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
    • Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
    • (2005) Blood , vol.106 , pp. 3760-3767
    • Rowe, J.M.1    Buck, G.2    Burnett, A.K.3
  • 11
    • 33846869976 scopus 로고    scopus 로고
    • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
    • Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950.
    • (2007) Blood , vol.109 , pp. 944-950
    • Fielding, A.K.1    Richards, S.M.2    Chopra, R.3
  • 12
    • 34548136113 scopus 로고    scopus 로고
    • Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
    • Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–1914.
    • (2007) Leukemia , vol.21 , pp. 1907-1914
    • Tavernier, E.1    Boiron, J.M.2    Huguet, F.3
  • 13
    • 84866094086 scopus 로고    scopus 로고
    • Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
    • Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
    • (2012) Blood , vol.120 , pp. 2032-2041
    • Gokbuget, N.1    Stanze, D.2    Beck, J.3
  • 15
    • 79551641737 scopus 로고    scopus 로고
    • Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
    • Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52:325–327.
    • (2011) Leuk Lymphoma , vol.52 , pp. 325-327
    • Piccaluga, P.P.1    Arpinati, M.2    Candoni, A.3
  • 16
    • 0029025026 scopus 로고
    • Constitutive endocytosis and degradation of CD22 by human B cells
    • Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154:4466–4475.
    • (1995) J Immunol , vol.154 , pp. 4466-4475
    • Shan, D.1    Press, O.W.2
  • 17
    • 33748778482 scopus 로고    scopus 로고
    • Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
    • Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44:1331–1341.
    • (2007) Mol Immunol , vol.44 , pp. 1331-1341
    • Carnahan, J.1    Stein, R.2    Qu, Z.3
  • 18
    • 84869434807 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin: time to resurrect?
    • Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012;30:3921–3923.
    • (2012) J Clin Oncol , vol.30 , pp. 3921-3923
    • Ravandi, F.1    Estey, E.H.2    Appelbaum, F.R.3
  • 19
    • 0030993376 scopus 로고    scopus 로고
    • CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling
    • Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504.
    • (1997) Annu Rev Immunol , vol.15 , pp. 481-504
    • Tedder, T.F.1    Tuscano, J.2    Sato, S.3    Kehrl, J.H.4
  • 20
    • 0033673757 scopus 로고    scopus 로고
    • Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research
    • Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des. 2000;6:1841–1879.
    • (2000) Curr Pharm Des , vol.6 , pp. 1841-1879
    • Thorson, J.S.1    Sievers, E.L.2    Ahlert, J.3
  • 21
    • 0023820894 scopus 로고
    • Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically
    • Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198–1201.
    • (1988) Science , vol.240 , pp. 1198-1201
    • Zein, N.1    Sinha, A.M.2    McGahren, W.J.3    Ellestad, G.A.4
  • 22
    • 0042303836 scopus 로고    scopus 로고
    • Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
    • Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3:386–390.
    • (2003) Curr Opin Pharmacol , vol.3 , pp. 386-390
    • Damle, N.K.1    Frost, P.2
  • 23
    • 0036007596 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
    • Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47–58.
    • (2002) Bioconjug Chem , vol.13 , pp. 47-58
    • Hamann, P.R.1    Hinman, L.M.2    Hollander, I.3
  • 24
    • 84856710962 scopus 로고    scopus 로고
    • The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
    • de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–264.
    • (2012) Leukemia , vol.26 , pp. 255-264
    • de Vries, J.F.1    Zwaan, C.M.2    De Bie, M.3
  • 25
    • 84880574025 scopus 로고    scopus 로고
    • Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    • Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–2736.
    • (2013) Cancer , vol.119 , pp. 2728-2736
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 26
    • 84860243682 scopus 로고    scopus 로고
    • Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
    • Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103:933–938.
    • (2012) Cancer Sci , vol.103 , pp. 933-938
    • Ogura, M.1    Hatake, K.2    Ando, K.3
  • 27
    • 84969791849 scopus 로고    scopus 로고
    • Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin
    • Betts AM, Haddish-Berhane N, Tolsma J, et al. Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin. AAPS J. 2016;18:1101–1116.
    • (2016) AAPS J. , vol.18 , pp. 1101-1116
    • Betts, A.M.1    Haddish-Berhane, N.2    Tolsma, J.3
  • 28
    • 10744229449 scopus 로고    scopus 로고
    • Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    • DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–1814.
    • (2004) Blood , vol.103 , pp. 1807-1814
    • DiJoseph, J.F.1    Armellino, D.C.2    Boghaert, E.R.3
  • 29
    • 4544320025 scopus 로고    scopus 로고
    • Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
    • DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10:8620–8629.
    • (2004) Clin Cancer Res , vol.10 , pp. 8620-8629
    • DiJoseph, J.F.1    Goad, M.E.2    Dougher, M.M.3
  • 30
    • 77951648118 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
    • Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–2093.
    • (2010) J Clin Oncol , vol.28 , pp. 2085-2093
    • Advani, A.1    Coiffier, B.2    Czuczman, M.S.3
  • 31
    • 84875434050 scopus 로고    scopus 로고
    • Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
    • Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573–583.
    • (2013) J Clin Oncol , vol.31 , pp. 573-583
    • Fayad, L.1    Offner, F.2    Smith, M.R.3
  • 32
    • 84938897233 scopus 로고    scopus 로고
    • A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
    • Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:2863–2869.
    • (2015) Leuk Lymphoma , vol.56 , pp. 2863-2869
    • Wagner-Johnston, N.D.1    Goy, A.2    Rodriguez, M.A.3
  • 33
    • 35548931579 scopus 로고    scopus 로고
    • Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
    • Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21:2240–2245.
    • (2007) Leukemia , vol.21 , pp. 2240-2245
    • Dijoseph, J.F.1    Dougher, M.M.2    Armellino, D.C.3    Evans, D.Y.4    Damle, N.K.5
  • 34
    • 84862786326 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
    • Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–411.
    • (2012) Lancet Oncol , vol.13 , pp. 403-411
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 35
    • 84890875516 scopus 로고    scopus 로고
    • Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
    • Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:369–372.
    • (2014) Pediatr Blood Cancer , vol.61 , pp. 369-372
    • Rytting, M.1    Triche, L.2    Thomas, D.3    O'Brien, S.4    Kantarjian, H.5
  • 36
    • 84982898563 scopus 로고    scopus 로고
    • A phase II Study of Weekly Inotuzumab Ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage
    • abstract
    • Advani AS, Stein AS, Kantarjian HM, et al. A phase II Study of Weekly Inotuzumab Ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. Blood. 2014;124:2255; abstract.
    • (2014) Blood , vol.124 , pp. 2255
    • Advani, A.S.1    Stein, A.S.2    Kantarjian, H.M.3
  • 37
    • 79955047304 scopus 로고    scopus 로고
    • Treating the “older” adult with acute lymphoblastic leukemia
    • Marks DI. Treating the “older” adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:13–20.
    • (2010) Hematology Am Soc Hematol Educ Program , vol.2010 , pp. 13-20
    • Marks, D.I.1
  • 38
    • 84988217496 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL)
    • Jabbour E, O'Brien SM, Jain N, et al. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL). J Clin Oncol. 2014;32(5 Suppl):abstr 7019.
    • (2014) J Clin Oncol , vol.32 , Issue.5 , pp. abstr 7019
    • Jabbour, E.1    O'Brien, S.M.2    Jain, N.3
  • 39
    • 84984677465 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
    • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
    • (2016) N Engl J Med , vol.375 , pp. 740-753
    • Kantarjian, H.M.1    DeAngelo, D.J.2    Stelljes, M.3
  • 40
    • 84923071079 scopus 로고    scopus 로고
    • Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
    • Jabbour E, O'Brien S, Huang X, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90:193–196.
    • (2015) Am J Hematol , vol.90 , pp. 193-196
    • Jabbour, E.1    O'Brien, S.2    Huang, X.3
  • 41
    • 84877733104 scopus 로고    scopus 로고
    • Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin
    • Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13:296–301.
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. 296-301
    • Kebriaei, P.1    Wilhelm, K.2    Ravandi, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.